The Safety of Anti-SARS-CoV-2 Vaccines: Vigilance Is Still Required

Journal of Clinical Medicine

Michel Goldman¹ 

[1] Institute for Interdisciplinary Innovation in Healthcare, Université Libre de Bruxelles, 1180 Brussels, Belgium;

关键词: COVID-19;    SARS-CoV-2;    vaccine;    mRNA lymphoma;    T cell;    autoimmunity;   

DOI  :  10.3390/jcm11051248

来源: DOAJ

【 摘 要 】

The opinion I put forward in this paper is that attention must continue to be paid to clinical observations compatible with a detrimental effect of anti-SARS-CoV-2 in certain diseases of immunological nature. Using the example of the atypical thrombocytopenic thromboses caused by adenoviral-vector-based vaccines, I argue that usual post-marketing pharmacovigilance programs may fail in identifying very rare vaccine-related disorders. Since the robust protective immunity induced by mRNA vaccines is related to their distinct capacity to induce strong stimulation of T follicular helper cells, I suggest that the safety of mRNA vaccines should be further assessed by appropriately designed epidemiological and mechanistic studies focusing on lymphoproliferative and autoimmune diseases in which T follicular helper cells were found to play a key role.

【 授权许可】

Unknown